NASDAQ:LAB Standard BioTools Q1 2026 Earnings Report $1.03 -0.01 (-0.96%) Closing price 04:00 PM EasternExtended Trading$1.03 0.00 (0.00%) As of 06:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Standard BioTools EPS ResultsActual EPSN/AConsensus EPS -$0.02Beat/MissN/AOne Year Ago EPSN/AStandard BioTools Revenue ResultsActual RevenueN/AExpected Revenue$17.80 millionBeat/MissN/AYoY Revenue GrowthN/AStandard BioTools Announcement DetailsQuarterQ1 2026Date5/5/2026TimeAfter Market ClosesConference Call DateTuesday, May 5, 2026Conference Call Time4:00PM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Standard BioTools Earnings HeadlinesCasdin funds buys Standard Biotools (LAB) shares worth $443,032May 21 at 12:57 PM | investing.comStandard BioTools Reports First Quarter 2026 Financial ResultsMay 5, 2026 | globenewswire.comPorter flew 3,300 miles to investigate this systemPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.May 22 at 1:00 AM | Porter & Company (Ad)Standard BioTools Receives Nasdaq Minimum Bid Price Deficiency NoticeApril 24, 2026 | tipranks.comStandard BioTools to Announce First Quarter 2026 Financial Results on May 5, 2026April 22, 2026 | finance.yahoo.comStandard BioTools Reports Fourth Quarter and Full Year 2025 Financial ResultsFebruary 24, 2026 | globenewswire.comSee More Standard BioTools Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Standard BioTools? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Standard BioTools and other key companies, straight to your email. Email Address About Standard BioToolsStandard BioTools (NASDAQ:LAB), Inc. (NASDAQ: LAB), formerly known as Fluidigm Corporation, is a life sciences tools company that develops and commercializes high-parameter, single-cell and spatial biology solutions. The company’s platforms integrate microfluidics, mass cytometry, sequencing and imaging to enable researchers to probe cellular heterogeneity, molecular interactions and complex tissue architecture. Its end users span academic institutions, pharmaceutical and biotechnology companies worldwide. The company’s flagship products include mass cytometry systems—such as the Helios and Hyperion Imaging System—for multiplexed protein analysis at single-cell resolution, and the Chromium-style single-cell genomic tools for high-throughput gene expression profiling. Standard BioTools also offers real-time PCR arrays, microfluidic access arrays and reagents designed to streamline workflows for target validation, drug discovery and translational research. Headquartered in South San Francisco, Standard BioTools maintains sales and support operations across North America, Europe and Asia, serving a global customer base of life science researchers and clinicians. The company invests in application development and cross-platform software that enables users to integrate proteomic, genomic and imaging data for deeper biological insights. In October 2023, the company rebranded from Fluidigm to Standard BioTools to reflect its unified approach to multi-omic and spatial biology solutions. Led by an experienced management team with backgrounds in life sciences innovation and instrumentation, Standard BioTools continues to expand its product portfolio and market reach. View Standard BioTools ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Overextended, e.l.f. Beauty Is Primed to Rebound in Back HalfDeere Beats Q2 Estimates, But Ag Weakness Weighs on OutlookNVIDIA Price Pullback? Don’t Count on It, Business Is AcceleratingMeta Platforms 10% Layoff Raises a Bigger Question About AI SpendingBiogen Stock Slides After Trial Miss, But Analysts Stay BullishTarget Shows Strengths, But Analysts Want to See MoreLowe's Finds Support at $215 After Q1 Earnings Sell-Off Upcoming Earnings AutoZone (5/26/2026)Marvell Technology (5/27/2026)PDD (5/27/2026)Synopsys (5/27/2026)Bank Of Montreal (5/27/2026)Bank of Nova Scotia (5/27/2026)Salesforce (5/27/2026)Snowflake (5/27/2026)Autodesk (5/28/2026)Costco Wholesale (5/28/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
